Lutetium Chloride

Summary

Lutetium Chloride (CHEMBL5316165) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5316165
Name	Lutetium Chloride
Type	Small molecule
Max phase	4

Also known as: Lutetium chloride (lucl3), NSC-132042

Parent form; salt/anhydrous children: CHEMBL5315062

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).